Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Cullinan Oncology Inc.

    NASDAQ: CGEM · Real-Time Price · USD
    8.72
    -0.02 (-0.23%)
    At close: Jun 17, 2025, 10:29 AM

    Cullinan Oncology Statistics

    Share Statistics

    Cullinan Oncology has 59.01M shares outstanding. The number of shares has increased by 1.52% in one year.

    Shares Outstanding

    n/a
    		 59.01M

    Shares Change (YoY)

    n/a
    		 1.52%

    Shares Change (QoQ)

    n/a
    		 0.49%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 35.92M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,937

    FTD / Avg. Volume

    n/a
    		 0.44%

    Short Selling Information

    The latest short interest is 6.18M, so 10.47% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.18M

    Short % of Shares Out

    n/a
    		 10.47%

    Short % of Float

    n/a
    		 12.12%

    Short Ratio (days to cover)

    n/a
    		 17.63

    Valuation Ratios

    The PE ratio is -3.91 and the forward PE ratio is -2.87. Cullinan Oncology's PEG ratio is 0.25.

    PE Ratio

    n/a
    		 -3.91

    Forward PE

    n/a
    		 -2.87

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 3.8

    PB Ratio

    n/a
    		 1.11

    P/FCF Ratio

    n/a
    		 -4.51

    PEG Ratio

    n/a
    		 0.25
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Cullinan Oncology.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 13.53, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 13.53

    Quick Ratio

    n/a
    		 13.53

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 -0.01

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,507,954.95

    Employee Count

    n/a
    		 111

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 117K

    Effective Tax Rate

    n/a
    		 -0.07%

    Stock Price Statistics

    The stock price has increased by -54% in the last 52 weeks. The beta is -0.04, so Cullinan Oncology's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.04

    52-Week Price Change

    n/a
    		 -54%

    50-Day Moving Average

    n/a
    		 8.1

    200-Day Moving Average

    n/a
    		 11.66

    Relative Strength Index (RSI)

    n/a
    		 55.09

    Average Volume (20 Days)

    n/a
    		 438,698

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 -306K

    Operating Income

    n/a
    		 -196.92M

    Net Income

    n/a
    		 -167.38M

    EBITDA

    n/a
    		 -167.15M

    EBIT

    n/a
    		 -167.46M

    Earnings Per Share (EPS)

    n/a
    		 -3.11
    Full Income Statement

    Balance Sheet

    The company has 83M in cash and 2.15M in debt, giving a net cash position of 80.85M.

    Cash & Cash Equivalents

    n/a
    		 83M

    Total Debt

    n/a
    		 2.15M

    Net Cash

    n/a
    		 80.85M

    Retained Earnings

    n/a
    		 -368.24M

    Total Assets

    n/a
    		 579.68M

    Working Capital

    n/a
    		 290.42M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -145.3M and capital expenditures 0, giving a free cash flow of -145.3M.

    Operating Cash Flow

    n/a
    		 -145.3M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -145.3M

    FCF Per Share

    n/a
    		 -2.7
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    CGEM does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CGEM is $33, which is 277.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $33

    Price Target Difference

    n/a
    		 277.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 8.38

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist